Join to View Full Profile
5323 Harry Hines BoulevardDallas, TX 75390
Phone+1 214-645-4673
Fax+1 214-645-2542
Dr. Kazmi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013- University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2007 - 2010
Aga Khan Medical CollegeClass of 2004
Certifications & Licensure
TX State Medical License 2017 - 2026
NM State Medical License 2013 - 2019
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib Start of enrollment: 2017 Jun 07
- Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study Start of enrollment: 2019 Nov 22
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- Presurgical Ablative Radiation Is Associated with Local Control and Immune Response in Pancreatic Cancer.Peter Q Leung, Eslam A Elghonaimy, Ahmed M Elamir, Megan Wachsmann, Song Zhang
Clinical Cancer Research. 2025-07-01 - 2 citationsTrastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients WithWild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.Kanwal Pratap Singh Raghav, Katherine A Guthrie, Benjamin Tan Jr, Crystal S Denlinger, Marwan Fakih
Journal of Clinical Oncology. 2025-04-10 - Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program.Chika Nwachukwu, Sukh Makhnoon, Marieshia Person, Meera Muthukrishnan, Syed Kazmi
Contemporary Clinical Trials Communications. 2024-06-01
Press Mentions
jb1-802 by JubilantSeptember 30th, 2021- Jubilant Therapeutics Strengthens Board of Directors with Addition of Leila Alland, M.D. And Announces Appointment of Jeremy Barton, M.D., as Strategic Advisor and Interim CMOAugust 16th, 2021
- Jubilant Therapeutics Announces Appointment of Luca Rastelli, Ph.D. As Chief Scientific OfficerMarch 8th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
